PRIMETEST II - Phase II Trial to Test New Predictors for Recurrence in Clinical Stage II A/B Seminoma Treated With Robot-Assisted Retroperitoneal Lymph Node Dissection

What this Trial Is About

Researchers are evaluating a new treatment approach for men with low-volume metastatic seminoma, a type of testicular cancer. This study, called PRIMETEST II, builds on previous research and aims to reduce the long-term side effects often caused by standard treatments like chemotherapy and radiation. By using robot-assisted surgery, the study hopes to improve quality of life and identify factors that predict cancer recurrence, allowing for more personalized care. The study involves a robot-assisted primary retroperitoneal lymph node dissection (RA-RPLND) to remove affected lymph nodes. Patients are divided into two groups based on risk factors: those with low risk will have surgery alone, while higher-risk patients may receive surgery followed by one cycle of chemotherapy with cisplatin, etoposide, and bleomycin. This personalized approach is designed to avoid unnecessary chemotherapy and its side effects for most patients. Participants will be monitored over several years to assess outcomes such as recurrence-free survival at three years, overall survival, quality of life, mental health, and potential complications from surgery. Researchers will also analyze tissue and blood samples to explore molecular markers linked to recurrence. The study includes yearly assessments for up to five years to gauge physical and mental health and track any side effects, aiming for a tailored treatment strategy that maintains excellent survival while minimizing long-term toxicity.

PRIMETEST II - Clinical Stage II A/B Seminoma Treated With RA-RPLND